Sun Pharmaceutical Industries shares jump 1.86% as ILUMYA approved in U.S. for Psoriatic Arthritis treatment
Why did Sun Pharmaceutical Industries Ltd shares jump today?
Sun Pharmaceutical Industries Ltd shares rose 1.86% to ₹1,795.7 during early morning trade on Friday, with the stock trading at 09:58 AM. The upward movement came after the company announced a significant regulatory milestone — ILUMYA® (tildrakizumab-asmn) has received approval in the United States for the treatment of adults with active Psoriatic Arthritis. The company intimated both the National Stock Exchange and BSE under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosing the press release with the announcement.
ILUMYA is an IL-23 inhibitor that is approved exclusively for healthcare provider-administered treatment. This new approval marks an important expansion of the drug's use beyond its existing indication for moderate-to-severe plaque psoriasis, opening up a larger patient population and a new revenue stream for Sun Pharma in the U.S. market. Psoriatic Arthritis is a chronic inflammatory condition affecting millions of adults worldwide, and the addition of a new approved therapy in this segment is expected to strengthen Sun Pharma's dermatology and immunology portfolio.
The news is seen as a positive catalyst for the stock because regulatory approvals for key branded products in the U.S. market directly contribute to the company's growth prospects and earnings visibility. Sun Pharma, one of India's largest pharmaceutical companies, has been steadily building its specialty portfolio, and this approval reinforces its position in the global immunology space. Investors responded positively, driving the share price higher in early trade as the market priced in the long-term revenue potential from ILUMYA's expanded label.
What does Sun Pharmaceutical Industries Ltd do?
Sun Pharmaceutical Industries Limited is a pharmaceutical company headquartered at Sun House on the Western Express Highway in Goregaon (E), Mumbai, Maharashtra, with its registered office at SPARC, Tandalja, Vadodara, Gujarat. The company is publicly listed on the National Stock Exchange of India and BSE Limited under the scrip symbol SUNPHARMA and scrip code 524715. Guided by its mission of "Reaching People. Touching Lives," Sun Pharma operates in the pharmaceutical sector and is involved in the development and commercialization of therapeutic treatments.
Among its product portfolio, the company markets ILUMYA® (tildrakizumab-asmn), a treatment approved in the United States for adults with active Psoriatic Arthritis. This reflects Sun Pharma's focus on addressing complex medical conditions and bringing approved therapeutic solutions to patients, particularly in the U.S. and international markets. The company's corporate and compliance operations are managed from its Mumbai headquarters, with dedicated secretarial and compliance functions ensuring adherence to regulatory requirements under the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
Sun Pharmaceutical Industries Ltd Financials
In CroresSun Pharmaceutical Industries Ltd demonstrated an upward financial trend in the quarter ending June 2026 compared to the quarter ending March 2026. Revenue rose from ₹14,559.75 Crores to ₹15,183.55 Crores, marking a sequential increase of approximately 4.28%. Profit followed a similar positive trajectory, growing from ₹2,714.03 Crores to ₹2,894.79 Crores, reflecting a sequential rise of roughly 6.66%. Notably, profit growth outpaced revenue growth during this period, suggesting improved profitability and effective cost management. Overall, the data indicates consistent growth in both top-line and bottom-line performance for the company across the two quarters.
Sun Pharmaceutical Industries Ltd Shareholding Pattern
Promoter holding stands at 52.68% of the total share capital. Foreign Institutional Investors (FIIs) hold 14.36% stake in the company, while Domestic Institutional Investors (DIIs) hold 22.27%. Public shareholders hold the remaining 10.7% stake in Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd FAQs
Q: Why did Sun shares jump 1.86% today?
ILUMYA (tildrakizumab-asmm) approved in the U.S. for the treatment of adults with active Psoriatic Arthritis. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Sun Pharmaceutical Industries Ltd?
As per the latest data, promoters hold 52.68% stake in Sun Pharmaceutical Industries Ltd, while FII holding stands at 14.36%. Domestic institutional investors hold 22.27%, and public shareholders account for 10.7% of the equity.
Q: What is the current stock price of Sun Pharmaceutical Industries Ltd?
Sun Pharmaceutical Industries Ltd shares are currently trading at ₹1795.7, recording a gain of 1.86% from the previous close.
Q: What is the market capitalization of Sun Pharmaceutical Industries Ltd?
The company currently has a market capitalization of ₹430848.57 crore, reflecting its valuation in the Indian equity market.